Abstract
Treatment of sporadic cardiac myxoma (CM) has always been a challenging task. Currently, surgical excision remains the only option; however, targeted drug discovery schemes are in progress in order to improve treatment strategies and efficacy. The molecular mechanisms behind CM pathogenesis are still not totally unveiled thus drug target identification is still at early steps, trying to compile structured data on the pathophysiology of CM, targets and targeting moieties. Five critical disease pathways involving molecules of seven functional groups have been recently shown by us to be associated with the pathogenesis of CM. In addition, 15 to 20 drug targets and their targeting molecules have also mapped on pathways in an effort to start decoding the molecular profiles based on which early efforts for CM patient stratification into targeted therapeutic regimes. The present review describes the current data and discusses critical issues in the field of targeted and personalized medicine of CM.
Keywords: Critical disease pathways, cardiac myxoma markers, drug targets, targeted therapy
Current Cancer Drug Targets
Title: Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma
Volume: 9 Issue: 6
Author(s): Debmalya Barh, Anil Kumar, Suvro Chatterjee and Triantafillos Liloglou
Affiliation:
Keywords: Critical disease pathways, cardiac myxoma markers, drug targets, targeted therapy
Abstract: Treatment of sporadic cardiac myxoma (CM) has always been a challenging task. Currently, surgical excision remains the only option; however, targeted drug discovery schemes are in progress in order to improve treatment strategies and efficacy. The molecular mechanisms behind CM pathogenesis are still not totally unveiled thus drug target identification is still at early steps, trying to compile structured data on the pathophysiology of CM, targets and targeting moieties. Five critical disease pathways involving molecules of seven functional groups have been recently shown by us to be associated with the pathogenesis of CM. In addition, 15 to 20 drug targets and their targeting molecules have also mapped on pathways in an effort to start decoding the molecular profiles based on which early efforts for CM patient stratification into targeted therapeutic regimes. The present review describes the current data and discusses critical issues in the field of targeted and personalized medicine of CM.
Export Options
About this article
Cite this article as:
Barh Debmalya, Kumar Anil, Chatterjee Suvro and Liloglou Triantafillos, Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma, Current Cancer Drug Targets 2009; 9 (6) . https://dx.doi.org/10.2174/156800909789271549
DOI https://dx.doi.org/10.2174/156800909789271549 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vertebrate Protein CTCF and its Multiple Roles in a Large-Scale Regulation of Genome Activity
Current Genomics Monitoring the Switch: The Warburg Effect and Targeted Proteomic Analysis of Cancer Metabolism
Current Proteomics Targeting Nanomedicine to Brain Tumors: Latest Progress and Achievements
Current Pharmaceutical Design Finding Recurrent Copy Number Alteration Regions: A Review of Methods
Current Bioinformatics Ultrasonic Echolocation Device for Assisting the Visually Impaired
Current Medical Imaging Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors
Current Alzheimer Research Editorial (Thematic Issue: Treatment of Cancer in the Elderly)
Anti-Cancer Agents in Medicinal Chemistry Association between MTHFR Gene Polymorphism and the Risk of Ovarian Cancer: A Meta-analysis of the Literature
Current Pharmaceutical Design The Cone Beam O-Arm Imaging System: Radiation Dose, Image Quality, and Clinical Applications
Recent Patents on Medical Imaging Harmonic Motion Imaging (HMI) for Tumor Imaging and Treatment Monitoring
Current Medical Imaging Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry Recent Advances on Liquid Chromatographic and Mass Spectrometric Analysis of Selective Estrogen Receptor Modulators (SERMs) in Biological Fluids
Current Chromatography A Comparison of the Toxicity of Mono, Bis, Tris and Tetrakis Phosphino Silver Complexes on SNO Esophageal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Stereological Quantification of Blood and Lymph Microvessels in Prostate Cancer. Its Relevance for the Anti-angiogenetic Therapy
Current Cancer Therapy Reviews Signal Transduction Pathways of Taxanes-Induced Apoptosis
Current Medicinal Chemistry - Anti-Cancer Agents Replacement Therapies in Metabolic Disease
Current Pharmaceutical Biotechnology Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
CNS & Neurological Disorders - Drug Targets Data Tagging in Medical Images: A Survey of the State-of-Art
Current Medical Imaging Pharmacophore Generation, Quantitative Structure-Activity Relationship (QSAR), and Molecular Dynamic Simulation of Newly Substituted N-(6- Chloro-3-cyano-4-phenyl-4H-chromen-2-yl)-2-(4-chloro-phenoxy)-acetamide for Anticancer Activity
Current Computer-Aided Drug Design Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design